UK-CH 4th Cell & Gene Therapy Exchange
Meet our FluidFM experts Dr. Tobias Beyer and Dr. Magid Haddouchi at the UK-CH CGT Exchange!
What Role Does Precise Cell Engineering Play in CGT? Ask Tobias Beyer and Magid Haddouchi at the UK-CH CGT Exchange.
Dr. Tobias Beyer (CSO) and Dr. Magid Haddouchi (CCO) will be at the UK-CH CGT Exchange in Lausanne ready to connect with peers from academia, biotech, and pharma to explore how precise genome engineering technologies can support the future of advanced therapies.
Dr. Tobias Beyer, CSO
Tobias is a cell biologist with expertise in CRISPR-based genome engineering, now developing FluidFM OMNIUM applications at Cytosurge.
Dr. Magid Haddouchi, CCO
Magid holds a PhD in Pharmaceutical Research and has expertise in biotech, medical devices, and XR/VR. At Cytosurge, he drives global strategy for the FluidFM® OMNIUM platform.
Why meet them?
Whether you're working on gene-edited cell therapies or navigating challenges in cell line development, Tobias and Magid bring fresh perspectives on how FluidFM-based intra-nuclear injection can help.
Let’s talk CellEDIT, bottlenecks, and new collaboration ideas!
- Got a challenge in gene editing?
- Looking to optimize your cell engineering workflow?
- Curious how single-cell precision can impact CGT pipelines?
They’re also attending the CGT Circle networking event the evening before—grab a drink and say hello!
Let’s connect in Lausanne and explore how next-gen tools like CellEDIT can empower your next breakthrough in Cell & Gene Therapy.